Today: 24 January 2026
Subscribe
Browse Category

NASDAQ:GPCR News 13 January 2026 - 15 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

New York, Jan 15, 2026, 13:24 EST — Regular session Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands. Why it matters now:…
15 January 2026
·····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk…
14 January 2026
········
Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

Structure Therapeutics stock jumps 14% as Roche-Genentech patent deal back in focus

NEW YORK, Jan 13, 2026, 12:18 EST — Regular session Shares of Structure Therapeutics climbed roughly 14% on Tuesday, adding to the stock’s recent swings. The move came as investors took a fresh look at the company’s newly announced patent licensing deal with Roche’s Genentech. (Reuters) This shift is significant as major drugmakers ramp up their push for obesity pills.…
13 January 2026
······

Stock Market Today

  • Weatherford International (WFRD) Appears Undervalued Amid Strong Multi-Year Gains
    January 23, 2026, 6:19 PM EST. Weatherford International (WFRD) has delivered a 28.9% return in the past year and over 10 times growth in five years. Despite strong share price performance, a Discounted Cash Flow (DCF) model values the stock at $308.05 per share, significantly above the recent price of $89.12, signaling the stock may be 71% undervalued. The DCF method factors in predicted free cash flows rising to $776 million by 2028 and continued growth through 2035. Simply Wall St rates the stock five out of six on undervaluation checks, highlighting compelling investment potential amid the oilfield services sector's evolving outlook. Investors should weigh these valuations carefully alongside sector risks and growth prospects.
Go toTop